B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice

Journal of Immunology

Volumn 181, Issue 5, 2008, Pages 2961-2972

  Li, Yongmei ^a   Chen, Fangqi ^a   Putt, Mary ^a   Koo, Yumee K ^b   Madaio, Michael ^c   Cambier, John C ^d   Cohen, Philip L ^a,e   Eisenberg, Robert A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA ANTIBODY; F 11172; HM 7916; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CD79 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; B CELL DEPLETION; BLOOD; BONE MARROW; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DERMATITIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; IN VIVO STUDY; INFLAMMATORY INFILTRATE; KIDNEY; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MEMORY CELL; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; SIALOADENITIS; SPLEEN; SUBMANDIBULAR GLAND; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; B LYMPHOCYTE; IMMUNOLOGY; METHODOLOGY; SURVIVAL RATE; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD79; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED MRL LPR; SURVIVAL RATE; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 51549109201     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.5.2961     Document Type: Article

References (27)

1. Rivera, A., C. C. Chen, N. Ron, J. P. Dougherty, and Y. Ron. 2001. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int. Immunol. 13: 1583-1593.
2. Lipsky, P. E. 2001. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2: 764-766.
3. Youinou, P., C. Jamin, J. O. Pers, C. Berthou, A. Saraux, and Y. Renaudineau. 2005. B lymphocytes are required for development and treatment of autoimmune diseases. Ann. NY Acad. Sci. 1050: 19-33.
4. Lund, F. E., B. A. Garvy, T. D. Randall, and D. P. Harris. 2005. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr. Dir. Autoimmun. 8: 25-54.
5. lpr mice independently of MHC class I antigen presentation. J. Immunol. 164: 1658-1662.
6. Yan, J., B. P. Harvey, R. J. Gee, M. J. Shlomchik, and M. J. Mamula. 2006. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J. Immunol. 177: 4481-4487.
7. Shlomchik, M. J., J. E. Craft, and M. J. Mamula. 2001. From T to B and back again: positive feedback in systemic autoimmune disease. Nat. Rev. Immunol. 1: 147-153.
8. Chan, O., and M. J. Shlomchik. 1998. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J. Immunol. 160: 51-59.
9. Sobel, E. S., T. Katagiri, K. Katagiri, S. C. Morris, P. L. Cohen, and R. A. Eisenberg. 1991. An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity. J. Exp. Med. 173: 1441-1449.
10. Chan, O., M. P. Madaio, and M. J. Shlomchik. 1997. The roles of B cells in MRL/lpr murine lupus. Ann. NY Acad. Sci. 815: 75-87.
11. Eisenberg, R., and D. Albert. 2006. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2: 20-27.
12. Ahuja, A., J. Shupe, R. Dunn, M. Kashgarian, M. R. Kehry, and M. J. Shlomchik. 2007. Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol. 179: 3351-3361.
13. Halpern, M. D., S. Y. Craven, P. L. Cohen, and R. A. Eisenberg. 1993. Regulation of anti-Sm autoantibodies by the immunoglobulin heavy chain locus. J. Immunol. 151: 7268-7272.
14. Koyama, M., K. Ishihara, H. Karasuyama, J. L. Cordell, A. Iwamoto, and T. Nakamura. 1997. CD79 alpha/CD79 beta heterodimers are expressed on pro-B cell surfaces without associated mu heavy chain. Int. Immunol. 9: 1767-1772.
15. Shlomchik, M. J., M. P. Madaio, D. Ni, M. Trounstein, and D. Huszar. 1994. The role of B cells in lpr/lpr-induced autoimmunity. J. Exp. Med. 180: 1295-1306.
16. Pinheiro, J. C., and D. M. Bates. 2000. Mixed-Effects Models in S and S-PLUS. Springer, New York.
17. Andrews, B. S., R. A. Eisenberg, A. N. Theofilopoulos, S. Izui, C. B. Wilson, P. J. McConahey, E. D. Murphy, J. B. Roths, and F. J. Dixon. 1978. Spontaneous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains. J. Exp. Med. 148: 1198-1215.
18. Nakamura, T., M. C. Sekar, H. Kubagawa, and M. D. Cooper. 1993. Signal transduction in human B cells initiated via Ig beta ligation. Int. Immunol. 5: 1309-1315.
19. Lang, P., J. C. Stolpa, B. A. Freiberg, F. Crawford, J. Kappler, A. Kupfer, and J. C. Cambier. 2001. TCR-induced transmembrane signaling by peptide/MHC class II via associated Ig-α/β dimers. Science 291: 1537-1540.
20. Fuentes-Panana, E. M., G. Bannish, F. G. Karnell, J. F. Treml, and J. G. Monroe. 2006. Analysis of the individual contributions of Igα(CD79a)- and Igβ(CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation. J. Immunol. 177: 7913-7922.
21. Waisman, A., M. Kraus, J. Seagal, S. Ghosh, D. Melamed, J. Song, Y. Sasaki, S. Classen, C. Lutz, F. Brombacher, et al. 2007. IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Igα/β. J. Exp. Med. 204: 747-758.
22. Weiser, P., C. Riesterer, and M. Reth. 1994. The internalization of the IgG2a antigen receptor does not require the association with Ig-alpha and Ig-beta but the activation of protein tyrosine kinases does. Eur. J. Immunol. 24: 665-671.
23. Cambridge, G., M. J. Leandro, M. Teodorescu, J. Manson, A. Rahman, D. A. Isenberg, and J. C. Edwards. 2006. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 54: 3612-3622.
24. Tedder, T. F., A. Baras, and Y. Xiu. 2006. Fcγreceptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin. Immunopathol. 28: 351-364.
25. Chen, W., M. S. Ford, K. J. Young, and L. Zhang. 2004. The role and mechanisms of double negative regulatory T cells in the suppression of immune responses. Cell. Mol. Immunol. 1: 328-335.
26. Ford, M. S., K. J. Young, Z. Zhang, P. S. Ohashi, and L. Zhang. 2002. The immune regulatory function of lymphoproliferative double negative T cells in vitro and in vivo. J. Exp. Med. 196: 261-267.
27. Polson, A. G., S. F. Yu, K. Elkins, B. Zheng, S. Clark, G. S. Ingle, D. S. Slaga, L. Giere, C. Du, C. Tan, et al. 2007. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin's lymphoma. Blood 110: 616-623.